



Mayzent in Bahrain

The NHRA named-patient coordination pathway — indicative 2026

NEUROLOGY · SECONDARY PROGRESSIVE MS

The clinical situation

Mayzent (siponimod) is an FDA-approved oral selective S1P1/S1P5 modulator indicated for relapsing forms of multiple sclerosis including active secondary progressive MS. Manufactured by Novartis. Standard dosing is CYP2C9 genotype-titrated over 5 days to a maintenance of 2 mg once daily (1 mg in CYP2C9*1/*3 or *2/*3); ambient-storage oral tablet with first-dose cardiac, ophthalmic, and CBC/LFT monitoring.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating neurologist confirms active SPMS with MRI/relapse evidence, CYP2C9 genotyping, baseline ECG, OCT, and VZV immunity.
- 2 Treating centre confirmed.** A Bahraini tertiary neurology / MS centre in Manama accepts the case.
- 3 NHRA named-patient application.** Clinical rationale, patient reference, and product details are filed with the NHRA.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; ambient-temperature shipment.
- 5 Arrival & administration.** Patient begins first-dose cardiac observation per label, titrates to maintenance; CBC, LFTs, OCT, and MRI per standard MS monitoring cadence.

Indicative economics

Reference US cash-pay range: USD 9,500–11,000 per 30-day supply. NHRA documentation, logistics, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete NHRA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and NHRA review. **Logistics.** Ambient-temperature shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Mayzent × Bahrain first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/mayzent-bahrain.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team